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Though Ultraviolet B radiation (290-320 nm; UVB) exerts profound systemic 
effects, it is absorbed only in the epidermis.  One important question in 
photobiology is how UVB signals are emanated from the epidermis.  
Microvesicle particles (MVP) are small (200-1000nm diameter) membrane-
bound vesicles released by numerous cell types and can be found in the 
circulation.  MVP can contain both nuclear and cytoplasmic components and 
are thought to provide a mechanism by which cells transmit signals 
systemically.  Though various stressors have been demonstrated to generate 
MVP, the ability of UVB to exert this effect has not been demonstrated.  
Previous studies from ours and other groups have established that through its 
ability to act as a pro-oxidative stressor, UVB generates oxidized 
glycerophosphocholine (Ox-GPC) lipids with Platelet-activating Factor-
receptor (PAF-R) agonist activity.  Our first studies examined the ability of 
UVB to stimulate the release of MVP.  Treatment of the human keratinocyte-
derived cell line HaCaT with UVB resulted in the release of MVP.  Treatment 
of HaCaT cells with the PAF-R agonist carbamoyl-PAF (CPAF) also generated 
MVP release.  Preincubation of HaCaT cells with antioxidants N-acetyl 
cysteine and vitamin C blocked MVP release in response to UVB, but had no 
effect on MVP release in response to CPAF.  To confirm that UVB generates 
MVP via PAF-R agonists, we used a human epithelial cell line with/without 
PAF-Rs.  UVB generated MVP only in the PAF-R-expressing (KBP) not the 
PAF-R-negative (KBM) cells.  Finally, we induced suction blisters on human 
skin explants and human skin in vivo and tested the ability of UVB irradiation 
of these blisters to induce MVP release into blister fluid.  These experiments 
determined that UVB generated MVP in human skin.  These studies describe 
a new pathway involving MVP generated following UVB-induced PAF agonist 
formation that could play an important role in transmitting systemic signals 
following this environmental pro-oxidative stressor.  
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1. UVB generates MVP in vitro in a
process involving PAF-R signaling.
2. UVB also generates
MVP
in human skin.
3. As MVP are thought
to be functional
signaling agents,
these studies could provide a mechanism
whereby UVB can generate systemic effects. 
SUMMARY
For in vitro experiments, the human keratinocyte-derived cell line HaCaT was used. HaCaT cells
were treated with UVB or the PAF-R agonist Carbamoyl-PAF (CPAF) or ethanol vehicle [3,5,7]. In
some experiments HaCaT cells were preincubated for one hour with 0.5mM each of the
antioxidants N-acetylcysteine and ascorbic acid before UVB/CPAF treatment. In some
experiments the PAF-R-negative human epidermoid cell line KB cells transduced with functional
PAF-Rs (KBP) or MSCV2.1 retroviral vector alone (KBM) were used [9]. At various times post-
treatment supernatants were removed and MVP isolated using differential centrifugation and
quantified using a NanoSight NS300 instrument using our previously published protocol [8,10].
For ex vivo experiments, we used skin discarded from human abdominoplasty experiments.
The skin was warmed to ~37-38 degrees C and suction blisters separating epidermis from
dermis were created using vacuum pumps and syringes (see Fig 5). Following blister
formation, the blisters were treated with either sham or UVB or topical CPAF in ethanol:DMSO
(1:9 v/v). Blister fluid was obtained and weighed in tared tubes. MVP were quantified as above.
For in vivo experiments, the volar forearm of human volunteers underwent suction blistering
and blisters were treated either sham or UVB. Again, blister fluid was removed and weighed
and MVP quantified as outlined above.
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Platelet activating factor (PAF) is a lipid-derived 1-alkyl-2-acetly-glycerophosphocholine,
produced in response to various stimuli that produces pronounced pro-inflammatory effects.
These include marked vasodilatory effects, increased vascular permeability, broncho-
constriction, and platelet activation. PAF has also been implicated in sepsis [1,2]. PAF acts
by binding to a cellular heterotrimeric G-protein coupled receptor PAF-R. This receptor is
found on many cell types including granulocytes, B-cells, epithelial cells (keratinocytes), and
some mesenchymal cells. PAF-R activation is known to induce intracellular calcium
mobilization and is expressed on keratinocytes. Recent studies have demonstrated that PAF
can be produced both enzymatically and through non-enzymatic oxidation of membrane
glycerophosphocholines (ox-GPCs) [3].
Figure 1- Biosynthesis of PAF through enzymatic and non-
enzymatic pathways
We and others have shown that in
addition to its pro-inflammatory effects,
PAF-R mediate pro-oxidative stressors
including UVB-induced acute
inflammation as well as delayed systemic
immunosuppression [4-6]. Regarding the
early acute effects of UVB, our previous
studies have demonstrated that the PAF-
R plays an important role in the pain
associated with sunburn [6], and
mediates the increased UVB sensitivity in
the Xeroderma Pigmentosum
Complementation group A (XPA) knock-
out mouse [7].
Microvesicle particles (MVP) are small
membrane-bound vesicles released by
numerous cell types and can be found in
the circulation. MVP can contain both
nuclear and cytoplasmic constituents and
are thought to provide a mechanism by
which cells transmit cells systemically [8].
MVP are 200-1000nm in diameter and
differ from smaller (40-200 nm)
exosomes.
Given that PAF is involved in UVB-mediated acute effects, these studies were
designed to define if MVP are released from keratinocytes following UVB, and
if PAF was involved in this process.
Figure 3. Effect of UVB and CPAF on MVP release in HaCaT cells. 
HaCaT cells were either A) control (0) or UVB-irradiated at various fluences or B) vehicle control 
or various doses of CPAF. Four hours after treatment, the supernatants were removed and MVPs 
quantified as outlined in Methods. C) HaCaT cells were treated with 3.6 KJ/m2 UVB or 100 nM
CPAF or control (CON), and were harvested 1 or 4 hrs post treatment. D).  HaCaT cells were 
preincubated with 0.5 mM of N-aceytcysteine and 0.5 mM Vitamin C for one hour before 
treatment with 3.6 KJ/m2 UVB or 100 nM CPAF.  The supernatants were removed and MVP 
measured 4 h later.  The data presented are the mean ± SD. MVP numbers of duplicate values 
from a representative experiment of at least three performed. *Statistically (p<0.05) significant 
changes from control values. NS: not statistically significant from control values.
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Figure 2.  Picture of MVP 
released from a cell
following stress
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Figure 4. Effect of UVB and CPAF on MVP
release in KBP vs KBM cells. KB cells stably
transduced with functional PAF-Rs (KBP) or empty
vector (KBM) were treated with 100 nM CPAF or
irradiated with 3.6 KJ/m2 UVB or control-treated. The
supernatants were harvested at 4 hrs post-treatment.
The data presented are the mean ± SD. MVP numbers
of duplicate values from a representative experiment
from at least three performed. *Statistically (p<0.05)
significant changes from control values. NS: not
statistically significant from control values.
Figure 5.  Suction blister 
formation ex vivo & in 
vivo
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Figure 6.  UVB generates MVP formation in skin.  
A).  Ex vivo blisters were treated with UVB (1 or 2.5 KJ/m2 
or  DMSO or CPAF (100 or 1000 ng).  B).  In vivo blisters 
were treated with sham or UVB (1KJ/m2). MVP tested at 2h.
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UVB generates microvesicle particles via Platelet-activating Factor-receptor 
signaling:  a novel pathway by which a skin-specific stimulus exerts systemic effects
